PTCE Exam Dumps - PTCB CPhT Questions and Answers

Insurance requires accurate “days supply” calculations.If a30-daysupply is incorrectly entered as a90-daysupply, the system will reject early refills.

????Reference:PTCE Pharmacy Billing and Reimbursement Guidelines.

Comprehensive and Detailed Step-by-Step Explanation:

Corticosteroidsare a class of medications used toreduce inflammation.Fluocinoloneis atopical corticosteroidused foreczema, psoriasis, and allergic reactions.

????Explanation of Answer Choices:✅B. Fluocinolone→Correct.Fluocinolone is a corticosteroidused in skin conditions.❌A. Progesterone→ Incorrect.Progesterone is a hormone, not a corticosteroid.❌C. Methyltestosterone→ Incorrect.Methyltestosterone is an androgen (male hormone).❌D. Spironolactone→ Incorrect.Spironolactone is a potassium-sparing diuretic, not a steroid.

????Reference:

FDA Drug Classification Database

USP Drug Information Handbook

Sertraline (Zoloft)is anSSRI antidepressantused formajor depressive disorder (MDD), anxiety, and other mood disorders.Suicidal ideation(thoughts of self-harm) is aserious and potentially life-threatening side effect, especially inyoung adults. A pharmacy technicianmust notify the pharmacist immediatelyif a patient reportssuicidal thoughts, as this may require immediate medical intervention.

A. Presents new insurance coverage→ Incorrect; this is an administrative issue, not a clinical concern.

B. Requests the refill two days early→ Incorrect; a slight early refill request does not indicate a safety concern.

D. Reports improved interest and motivation→ Incorrect; this is apositive treatment response, not an urgent issue.

Other Answer Choices Explained:References:

FDA Black Box Warning for SSRIs – Suicide Risk in Young Adults

PTCB PTCE Exam Content Outline (Medication Safety & Patient Communication)

Lexicomp Drug Monograph for Sertraline (Zoloft)

ARisk Evaluation and Mitigation Strategy (REMS)program is required by theFDAfor certain medications that have serious safety concerns, ensuring their risks do not outweigh their benefits.Mycophenolateis subject to a REMS program due to its severe teratogenic effects.

(A) Sertraline❌Not Subject to REMS

Sertraline (Zoloft) is aSelective Serotonin Reuptake Inhibitor (SSRI)used to treat depression and anxiety.

While SSRIs can carry arisk of birth defects (such as persistent pulmonary hypertension in newborns - PPHN),sertraline is not included in the REMS program.

(B) Ondansetron❌Not Subject to REMS

Ondansetron (Zofran) is anantiemeticused to prevent nausea and vomiting.

While some studies suggest a possible increased risk of congenital defects, it isnot part of a REMS program.

(C) Montelukast❌Not Subject to REMS

Montelukast (Singulair) is aleukotriene receptor antagonist (LTRA)used forasthma and allergies.

It has aBoxed Warningfor mental health side effects butis not subject to a REMS program for pregnancy risks.

(D) Mycophenolate✅Correct – Subject to REMS

Mycophenolate (CellCept, Myfortic)is animmunosuppressantused to prevent organ rejection in transplant patients.

It carries ahigh risk of birth defects and miscarriage, making pregnancy preventionmandatorywhile taking the medication.

TheMycophenolate REMS Programrequires:

Mandatory counselingon pregnancy risks

Negative pregnancy testsbefore starting therapy

Use of effective contraceptionbefore, during, and after treatment

FDA REMS Program for Mycophenolate:https://www.mycophenolaterems.com/

FDA REMS Program Overview: https://www.fda.gov/drugs/risk-evaluation-and-mitigation-strategies-rems

PTCB Exam Content Outline – Medication Safety & Risk Management

Analysis of Answer Choices:References for Pharmacy Technicians:

Alot numberis a unique identifier assigned to a specific batch of a medication during manufacturing.

TheNational Drug Code (NDC)andserial numberare different from the lot number.

On medication stock bottles, the lot number is often preceded by"(10)", which is present in this case:

(10)ABC123→This represents the lot number.

B. 55555444422→ This appears to be aGTIN (Global Trade Item Number), which identifies the product but is not the lot number.

C. 051526→ This could represent a manufacturer’s internal code or part of the packaging details, but not the lot number.

D. 11262026→ This follows the(21) identifier, which represents theexpiration date (November 26, 2026).

PTCB PTCE Exam Content Outline – Medication Labeling and Lot Numbers

FDA Drug Supply Chain Security Act (DSCSA)– Provides guidance on tracking drug batches.

USP Chapter <1079> Good Storage and Distribution Practices– Covers stock bottle labeling and identification.

Why Other Answers Are Incorrect?Pharmacy Technician References:

TheNational Drug Code (NDC)is a10- or 11-digit numberthat uniquely identifies drugs in the U.S.

NDC format:

First set of numbers (Labeler Code):Identifies the manufacturer.

Middle set of numbers (Product Code):Identifies the specificdrug, strength, and dosage form(important for accurate product selection).

Last set of numbers (Package Code):Identifies the package size and type.

Why Other Options Are Incorrect:

A. Identification of therapeutic class?❌NDC codes do not indicate a drug’s therapeutic class.

B. Locating expired medication?❌Expiration dates are printed separately on the packaging.

C. Proper storage of the medication?❌Storage requirements are determined by themanufacturer’s label, not the NDC.

????Reference:FDA NDC Directory Guidelines, PTCE Exam Study Guide.

Cefdinir is a cephalosporin (β-lactam) antibiotic. Patients with a penicillin allergy can have cross-reactivity with cephalosporins due to similar β-lactam structures, although the risk is lower with later generations like cefdinir. Because of this known potential cross-sensitivity, it is standard practice to assess for penicillin allergy when dispensing cephalosporins. Option A is incorrect because penicillin allergy is not an absolute, specific contraindication to cefdinir in all cases; risks must be assessed. Option B is incorrect (fluoroquinolones are unrelated class). Option D is overly general and not a standard rationale.

References (Pharmacy Technician documents/Study Guides):

• PTCB/ExCPT study materials on antibiotic classes and allergy cross-reactivity (β-lactams: penicillins and cephalosporins).

• ISMP medication safety guidance on allergy screening and β-lactam cross-sensitivity.

• Community pharmacy counseling references on assessing penicillin allergies before dispensing cephalosporins.

Look-alike/sound-alike (LASA) drug name pairs (e.g., hydralazine vs hydroxyzine) are a well-recognized cause of wrong-drug errors. ISMP and technician training resources emphasize verifying the National Drug Code (NDC) and/or barcode scanning against the prescription to ensure the correct drug, strength, and manufacturer are selected before counting. The NDC uniquely identifies the labeler, product, and package; thus, verifying the NDC is a stronger safety check than relying on tablet color (which can vary) or lot number (used for traceability/recalls, not drug selection). Strength verification is important, but first you must ensure the correct drug; NDC verification accomplishes both drug and strength confirmation.

References (Pharmacy Technician documents / Study Guides):

• ISMP community pharmacy medication safety guidance on LASA verification and barcode/NDC checks.

• PTCB/ExCPT Medication Safety sections: LASA risk-reduction strategies; NDC use in product selection.

• FDA/Drug listing education: NDC identifies labeler–product–package; used to ensure correct product selection.

DEA requires allcontrolled substance prescriptionsto include thedate of issueas per21 CFR 1306.05(a).

Other required elements:

Patient’s full name and address

Drug name, strength, dosage form, quantity

Directions for use

Prescriber’s name, address,DEA number, and signature

????Reference:DEA Controlled Substance Act;21 CFR 1306.05.

Experiencingphotosensitivity(increased sensitivity to sunlight) as a result of takingciprofloxacinis an example of anadverse drug reaction (ADR). Thisunexpectedandundesirableeffect occurs in some individuals due tofluoroquinolones causing cellular damage from UV exposure.

A. Intended effect→ Incorrect; the intended effect of ciprofloxacin isbacterial infection treatment, not photosensitivity.

C. Synergistic effect→ Incorrect; asynergistic effectoccurs whentwo drugs work togetherto produce a greater effect, which is not the case here.

D. Anaphylactic reaction→ Incorrect;anaphylaxisis asevere allergic reactionwithrespiratory distress, hypotension, and swelling, not photosensitivity.

Other Answer Choices Explained:References:

PTCB PTCE Exam Content Outline (Medication Safety & Side Effects)

Lexicomp Drug Monograph for Ciprofloxacin

FDA Fluoroquinolone Safety Warnings